Evaluation of the Antimicrobial Effectiveness of CHG/IPA

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1935 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-17

Study Completion Date

2019-12-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This single site study is a randomized, controlled, partially-blinded design enrolling a minimum of 516 healthy volunteers, where each subject will receive two of the planned study products on the product application sites of the abdomen and/or groin.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 1a/b Study on Safety of IMX101 in H. Pylori-negative and H. Pylori-infected Healthy Volunteers

NCT03270800

Helicobacter Pylori Infected Subjects Helicobacter Pylori Naive Subjects

COMPLETED PHASE1

Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections

NCT01726023

Complicated Intra-abdominal Infection

COMPLETED PHASE3

Fast Assay for Pathogen Identification and Characterization

NCT03841162

Bacteremia Sepsis Septic Shock

COMPLETED

Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections

NCT01445678

Complicated Intra-abdominal Infection

COMPLETED PHASE3

Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis

NCT01345929

Complicated Urinary Tract Infection Pyelonephritis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To demonstrate the antimicrobial activity of the Investigational Product (IP) by comparing counts of resident skin microbes, obtained after IP application to intact skin of the abdomen and groin, to counts obtained prior to application.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Microbial Colonization

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Healthy adult volunteers that meet inclusion/exclusion criteria will be randomized to receive 2 of the 4 products on bilateral site on the abdomen and/or groin.

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study products cannot be blinded to staff member(s) performing product applications, sample collections.

Staff member(s) performing bacterial enumeration will be blinded from the identification of all study product assignments.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Investigational Product

Skin will be prepared with investigational product

Group Type EXPERIMENTAL

Investigational Product

Intervention Type COMBINATION_PRODUCT

2%(w/v) Chlorhexidine in 70%(v/v) Isopropyl skin preparation

Reference Standard

Skin will be prepared with reference standard

Group Type OTHER

Reference Standard

Intervention Type OTHER

60% (v/v) 1-propanol skin preparation

Active Control

Skin will be prepared with active comparator

Group Type ACTIVE_COMPARATOR

Active Comparator

Intervention Type COMBINATION_PRODUCT

ChloraPrep® SEPP® skin preparation

Negative Control

Skin will be prepared with negative control

Group Type OTHER

Negative Control

Intervention Type OTHER

0.9% Normal Saline skin preparation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Investigational Product

2%(w/v) Chlorhexidine in 70%(v/v) Isopropyl skin preparation

Intervention Type COMBINATION_PRODUCT

Reference Standard

60% (v/v) 1-propanol skin preparation

Intervention Type OTHER

Active Comparator

ChloraPrep® SEPP® skin preparation

Intervention Type COMBINATION_PRODUCT

Negative Control

0.9% Normal Saline skin preparation

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Read, understand, and provide signed informed consent.
2. Are healthy subjects in good general health
3. Are 18 years of age or older
4. If females of childbearing potential, are using an acceptable form of birth control for at least 28 days immediately preceding Day 1 and throughout the duration of the study. Acceptable methods are established, effective hormonal contraception (oral/implant/injectable/transdermal/intra-vaginal), intra-uterine device \[IUD\], diaphragm with spermicide, condom with spermicide, abstinence, bilateral tubal ligation, or are in a monogamous relationship with a partner who has had a vasectomy
5. In the case of females of childbearing potential, have a negative urine pregnancy test (UPT) on Product Application Day prior to any applications of the study products.
6. Are free of any systemic or dermatologic disorder, which, in the opinion of the Investigator, will interfere with the study results or increase the risk of AEs.
7. Have minimal Screening Day bacterial count.

Exclusion Criteria

1. Have had exposure to topical or systemic antimicrobials or any other product known to affect the normal microbial flora of the skin, antibiotics or steroids (other than hormones for contraception or post-menopausal reasons) within the product restriction period and for the remainder of the study. Restrictions include, but are not limited to antimicrobial soaps, antiperspirants/deodorants, shampoos, lotions, perfumes, after shaves, and colognes.
2. Subjects who have a history of skin allergies.
3. Have known allergies or sensitivity to vinyl, latex (rubber), alcohols, metals, inks, common consumer/beauty products, tape adhesives, or to common antibacterial agents found in soaps, lotions, or ointments, particularly chlorhexidine, or any other product components.
4. Swimming in chemically treated pools or bathing in hot tubs, spas and whirlpools within the product restriction period and for the remainder of the study.
5. Use of tanning beds, hot waxes, or depilatories, including shaving (in the applicable product application areas) within the product restriction period and for the remainder of the study.
6. Have had exposure of the product application sites to strong detergents, acids, bases, bug repellant, fabric softener-treated clothing, UV treated clothing, other household chemicals in the applicable product application areas or other irritants during the product restriction period or during the study period.
7. Have a history of skin cancer within 6 inches of applicable product application areas, or are currently being treated for skin cancer or have received treatment for any type of internal cancer within the 5 years prior to enrollment.
8. Subjects who have a history of asthma, diabetes, hepatitis B or C, an organ transplant, mitral valve prolapse with a heart murmur, congenital heart disease, lupus, Crohn's disease, medicated multiple sclerosis, internal prosthesis or any immunocompromised conditions (such as AIDS or HIV positive).
9. A currently active skin disease or inflammatory skin condition (for example contact dermatitis) anywhere on the body.
10. Any tattoos or scars (including stretch marks) on the product application sites or within 2 inches of the product application sites; skin blemishes or warts may be permissible with the specific approval of the Investigator or consulting physician.
11. Dermatoses, cuts, lesions, active skin rashes, scabs, breaks in the skin or other skin disorders within 6 inches on or around the product application sites.
12. Subjects who have showered or bathed within at least 72 hours of the Product Application Day. Sponge baths may be taken, however, the lower abdomen and upper thigh region must be avoided.
13. Subjects who have an irritation score of 1 or greater (any redness, swelling, rash, or dryness present at any product application area) for any individual skin condition prior to the Product Application Day baseline sample collection.
14. Are females who are pregnant, plan to become pregnant during the study, or are breastfeeding a child.
15. Are unable to adhere to or understand the protocol.
16. Have used an investigational drug or participated in an investigational study within 30 days prior to signing the informed consent for this study or are currently participating in a clinical study.
17. Are employed by or are a family member of staff of BD or the study site conducting the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes